Ezzedine Khaled, Painchault Caroline, Brignone Melanie
Department of Dermatology, Hôpital Henri Mondor, FR-94000 Creteil, France.
Acta Derm Venereol. 2021 Jan 4;101(1):adv00358. doi: 10.2340/00015555-3690.
A systematic literature review was conducted to identify and qualitatively assess randomized controlled trials in immunocompetent patients ≥ 18 years with head- region lesions of actinic keratoses who were treated with field-directed, lesion-directed and other therapies. Network meta-analysis was used to quantitatively evaluate field-directed therapies (5-fluorouracil formulations, diclofenac sodium, imiquimod, ingenol mebutate, 5-aminolevulinic acid or methyl aminolevulinate plus photodynamic therapy) using complete clearance or partial clearance of actinic keratoses lesions, and adverse event-related withdrawals as a proxy of acceptability. Of 2,863 references identified, 75 trials reported in 151 publications were included. In summary, comparative network meta-analysis evaluation showed that 5-fluorouracil formulations were the most efficacious interventions examined. 5-fluorouracil 4%, which was recently approved, showed a comparable efficacy profile to 5-fluorouracil 5%, and had satisfactory acceptability outcomes.
我们进行了一项系统的文献综述,以识别和定性评估年龄≥18岁、免疫功能正常、患有头面部光化性角化病病变的患者接受区域定向、病损定向和其他治疗的随机对照试验。采用网状Meta分析,以光化性角化病病变的完全清除或部分清除以及与不良事件相关的撤药作为可接受性的替代指标,对区域定向治疗(5-氟尿嘧啶制剂、双氯芬酸钠、咪喹莫特、鬼臼毒素、5-氨基酮戊酸或甲基氨基酮戊酸加光动力疗法)进行定量评估。在识别出的2863篇参考文献中,纳入了151篇出版物中报告的75项试验。总之,比较网状Meta分析评估表明,5-氟尿嘧啶制剂是所研究的最有效的干预措施。最近获批的4% 5-氟尿嘧啶与5% 5-氟尿嘧啶疗效相当,且具有令人满意的可接受性结果。